| Status |
Official Title |
Lead Investigator |
Last Updated |
| Finalised |
Study of impact of EU label changes for fluoroquinolone containing medicinal products for systemic and inhalation use - post-referral prescribing trends |
Professor Deborah Layton |
30/10/2020 |
| Finalised |
Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study |
Professor Daniel Prieto-Alhambra |
06/07/2020 |
| Finalised |
Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals to Assess their Knowledge on Dosing and Administration of Obizur® (Susoctocog alfa) in 6 European Countries |
Dr Dorothea von Bredow |
05/05/2020 |
| Finalised |
A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases |
Dr Massoud Toussi |
18/12/2019 |
| Finalised |
Severe hypersensitivity reactions associated with iv iron containing medicinal products in countries of the European Economic Area – before and after implementation of risk minimisation measures |
Dr Gohlke Annegret |
13/06/2019 |
| Ongoing |
Non-Interventional Post-Authorisation Safety Study (NI-PASS) as an effectiveness check of an additional Risk Minimisation Measure (aRMM) (Direct Healthcare Professional Communication [DHPC]) for Bendamustine |
Dr Massoud Toussi |
07/10/2020 |
| Ongoing |
preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems [TRIUMPH] |
Dr J. Scott Andrews |
09/04/2020 |
| Ongoing |
RANITIDINE AND OTHER HISTAMINE-H2-RECEPTOR ANTAGONISTS – A DRUG UTILISATION STUDY |
Dr Katia Verhamme |
03/02/2020 |
| Ongoing |
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study |
Professor Prieto Dani |
24/01/2020 |
| Ongoing |
A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the dosing recommendation to avoid very low LDL-C levels |
Dr Trial Transparency Team Trial Transparency Team |
08/04/2019 |
| Planned |
The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer |
Miss Lane Jennifer |
09/12/2020 |
| Planned |
Patient and Prescriber Survey: Effectiveness measures to investigate awareness, knowledge and adherence to the Risk Minimisation Measures (RMMs) of the Pregnancy Prevention Program (PPP) for Oral Retinoids (Acitretin, Alitretinoin, and Isotretinoin) |
Dr Massoud Toussi |
16/11/2020 |
| Planned |
GENESIS: AIMOVIG® Pregnancy Exposure Registry (20180125) |
Dr Global Development Leader Amgen Inc. |
13/11/2020 |
| Planned |
Registry to study factors that may impact COVID-19 occurrence and severity |
Dr Dreyer Nancy |
13/07/2020 |
| Planned |
A post-authorization safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring - a population-based retrospective study |
Professor Deborah Layton |
24/06/2020 |
| Planned |
A Drug Utilisation Study extension (DUS ext.) of valproate and related substances, in Europe, using databases |
Dr Massoud Toussi |
28/04/2020 |
| Planned |
Surveys among Health Care Professionals and Patients to assess their knowledge and behaviour with respect to the new (2018) Risk Minimization Measures for valproate use in Europe. |
Dr Massoud Toussi |
28/04/2020 |
| Planned |
Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilization study (DUS) using secondary data |
Dr Massoud Toussi |
18/11/2019 |
| Planned |
Prescriber survey to evaluate the awareness to risk minimisation measures for mitoxantrone-containing medicinal products in the treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability |
Dr Massoud Toussi |
05/11/2019 |
